- Home
- SLI vs ATXS Comparison
SLI vs ATXS Comparison
Compare SLI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- ATXS
- Stock Information
- Founded
- SLI 1998
- ATXS 2008
- Country
- SLI Canada
- ATXS United States
- Employees
- SLI N/A
- ATXS N/A
- Industry
- SLI Major Chemicals
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SLI Industrials
- ATXS Health Care
- Exchange
- SLI Nasdaq
- ATXS Nasdaq
- Market Cap
- SLI 595.8M
- ATXS 676.1M
- IPO Year
- SLI N/A
- ATXS 2015
- Fundamental
- Price
- SLI $3.97
- ATXS $12.37
- Analyst Decision
- SLI Strong Buy
- ATXS Hold
- Analyst Count
- SLI 3
- ATXS 6
- Target Price
- SLI $5.25
- ATXS $24.33
- AVG Volume (30 Days)
- SLI 3.9M
- ATXS 931.7K
- Earning Date
- SLI 11-10-2025
- ATXS 11-12-2025
- Dividend Yield
- SLI N/A
- ATXS N/A
- EPS Growth
- SLI N/A
- ATXS N/A
- EPS
- SLI N/A
- ATXS N/A
- Revenue
- SLI N/A
- ATXS $706,000.00
- Revenue This Year
- SLI N/A
- ATXS N/A
- Revenue Next Year
- SLI N/A
- ATXS N/A
- P/E Ratio
- SLI N/A
- ATXS N/A
- Revenue Growth
- SLI N/A
- ATXS N/A
- 52 Week Low
- SLI $1.08
- ATXS $3.56
- 52 Week High
- SLI $6.40
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- SLI 55.43
- ATXS 62.15
- Support Level
- SLI $3.55
- ATXS $12.29
- Resistance Level
- SLI $4.42
- ATXS $12.57
- Average True Range (ATR)
- SLI 0.32
- ATXS 0.21
- MACD
- SLI 0.07
- ATXS -0.17
- Stochastic Oscillator
- SLI 69.78
- ATXS 38.30
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.